Kirsten Fischer

5PUBLICATIONS
19CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 27, 2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

|Jul 31, 2024
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Othman Al-Sawaf, Sandra Robrecht, Can Zhang

|Dec 09, 2023
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.

Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht

|Apr 18, 2023
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Othman Al-Sawaf, Can Zhang, Hyun Yong Jin

Pageof 1

Frequent Collaborators

5 joint publications

Othman Al-Sawaf

3 joint publications

Martin Peifer

3 joint publications

Stephan Stilgenbauer

3 joint publications

Carsten Utoft Niemann